ENDRA Life Sciences (NASDAQ:NDRA) Posts Quarterly Earnings Results, Beats Expectations By $0.14 EPS

Posted by Francis Steltz on May 15th, 2026

ENDRA Life Sciences (NASDAQ:NDRA – Get Free Report) issued its earnings results on Friday. The company reported ($1.09) EPS for the quarter, beating the consensus estimate of ($1.23) by $0.14, FiscalAI reports.

ENDRA Life Sciences Stock Down 12.0%

NDRA stock traded down $0.69 during mid-day trading on Friday, reaching $5.05. 44,977 shares of the company traded hands, compared to its average volume of 80,417. The stock has a market cap of $6.26 million, a price-to-earnings ratio of -0.57 and a beta of -0.11. ENDRA Life Sciences has a fifty-two week low of $2.91 and a fifty-two week high of $11.96. The firm’s 50 day moving average price is $4.55 and its 200 day moving average price is $4.73.

Analysts Set New Price Targets

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of ENDRA Life Sciences in a research note on Monday, April 20th. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $30.00.

Check Out Our Latest Stock Analysis on ENDRA Life Sciences

ENDRA Life Sciences Company Profile

(Get Free Report)

ENDRA Life Sciences, Inc (NASDAQ: NDRA) is a medical technology company headquartered in Ann Arbor, Michigan, that focuses on the development and commercialization of Thermoacoustic Enhanced Ultrasound (TAEUS™) imaging. The company’s proprietary TAEUS platform combines conventional ultrasound with thermoacoustic signals to provide non-invasive, real-time temperature monitoring of soft tissue. This technology is designed to improve the safety, efficacy and outcomes of thermal ablation procedures and other heat-based therapies.

ENDRA’s core product line centers on a compact, easy-to-integrate device that augments existing ultrasound systems.